ArticleTranslational oncology2017

BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.

Jieyu Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.